Biotech Values

[DewDiligence]

MNTA’s CEO tells why at-risk launch of 40mg Copaxone is likely:

http://seekingalpha.com/article/3995954-momenta-pharmaceuticals-mnta-ceo-craig-wheeler-q2-2016-results-earnings-call-transcript?part=single

…launching at risk here is Sandoz’s decision under our contract… What I can say is that in the generic world, when you are looking at patents—this patent is one that is going to rise or fall based on some pretty clear and simple standards of obviousness et cetera. So, it’s different than when you are looking at a complex issue of molecular weight measurement and things.

So, this is going to be one that is going to be much clearer to understand t he Court’s decision and therefore will be a much easier decision on launch… of course you will anticipate appeals, but this is a…common situation…and Sandoz is a very sophisticated generic company. So, I anticipate that we will see pretty good logic here for launching. And as I said in the call, we are preparing for first quarter launch and you should take that as we are all well aware that there will be an appeal.